A detailed history of Goldman Sachs Group Inc transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 169,678 shares of ORIC stock, worth $1.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
169,678
Previous 50,788 234.09%
Holding current value
$1.28 Million
Previous $467,000 399.57%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$8.04 - $16.03 $955,875 - $1.91 Million
118,890 Added 234.09%
169,678 $2.33 Million
Q4 2023

Feb 13, 2024

BUY
$5.41 - $9.43 $14,239 - $24,819
2,632 Added 5.47%
50,788 $467,000
Q3 2023

May 14, 2024

SELL
$6.05 - $9.28 $15,923 - $24,424
-2,632 Reduced 5.18%
48,156 $291,000
Q3 2023

Nov 14, 2023

SELL
$6.05 - $9.28 $48,484 - $74,369
-8,014 Reduced 14.27%
48,156 $291,000
Q2 2023

May 14, 2024

SELL
$4.95 - $8.4 $188,837 - $320,451
-38,149 Reduced 40.45%
56,170 $435,000
Q2 2023

Aug 14, 2023

SELL
$4.95 - $8.4 $188,837 - $320,451
-38,149 Reduced 40.45%
56,170 $435,000
Q1 2023

May 14, 2024

BUY
$4.26 - $6.75 $284,406 - $450,643
66,762 Added 242.27%
94,319 $537,000
Q1 2023

May 11, 2023

BUY
$4.26 - $6.75 $401,798 - $636,653
94,319 New
94,319 $537,000
Q3 2022

May 14, 2024

SELL
$3.28 - $5.24 $114,242 - $182,509
-34,830 Reduced 55.83%
27,557 $88,000
Q3 2022

Nov 10, 2022

SELL
$3.28 - $5.24 $114,242 - $182,509
-34,830 Reduced 55.83%
27,557 $0
Q2 2022

May 14, 2024

BUY
$2.7 - $7.07 $31,317 - $82,004
11,599 Added 22.84%
62,387 $280,000
Q2 2022

Aug 15, 2022

BUY
$2.7 - $7.07 $5,618 - $14,712
2,081 Added 3.45%
62,387 $280,000
Q1 2022

May 16, 2022

BUY
$4.54 - $16.1 $74,415 - $263,895
16,391 Added 37.32%
60,306 $322,000
Q4 2021

Feb 14, 2022

BUY
$12.01 - $20.3 $41,962 - $70,928
3,494 Added 8.64%
43,915 $645,000
Q3 2021

Nov 10, 2021

BUY
$15.9 - $25.22 $642,693 - $1.02 Million
40,421 New
40,421 $845,000

Others Institutions Holding ORIC

About Oric Pharmaceuticals, Inc.


  • Ticker ORIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,576,700
  • Market Cap $298M
  • Description
  • ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...
More about ORIC
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.